Afrigen Biologics

Executive Summary

Afrigen Biologics, a South African private biopharmaceutical company founded in 2017, is at the forefront of developing and manufacturing affordable biologics tailored to diseases prevalent in Africa. With $120 million raised, the company operates a commercial-stage facility in Cape Town and employs 200-500 staff. Its mission aligns with global health equity, focusing on vaccines and biosimilars to address infectious diseases that disproportionately affect the continent. Notable achievements include the development of Africa's first mRNA vaccine candidate (AfriVax) with support from the WHO and the Medicines Patent Pool, leveraging a technology transfer hub model. This breakthrough positions Afrigen as a key player in regional pandemic preparedness and sustainable vaccine production, reducing reliance on foreign suppliers. The company's pipeline targets COVID-19, tuberculosis, and other neglected diseases, with additional biosimilar programs for chronic conditions. Given its strategic importance, Afrigen has garnered partnerships with global health organizations and is scaling up manufacturing capacity to meet local demand. However, as a private entity, its financial details remain opaque, and its valuation is estimated. The company faces challenges typical of African biotech, including regulatory hurdles and limited financing, but benefits from strong political and philanthropic support.

Upcoming Catalysts (preview)

• Q3 2026WHO prequalification or regulatory approval for AfriVax (mRNA COVID-19 vaccine)65% success
• Q4 2026Strategic partnership or grant for tuberculosis vaccine development60% success
• TBDLaunch of first biosimilar product in Sub-Saharan Africa50% success